MAPT and Alzheimer disease: Therefore, the findings by Tramutola and colleagues are in contrast to the notion that overactivation of GSK3β leads to tau hyperphosphorylation and questions strategies to inhibit/attenuate GSK3β as therapeutics for AD as to date inhibitors have shown little benefit in clinical trials [75].